Biotricity Inc. (BTCY): Price and Financial Metrics
BTCY Price/Volume Stats
|Current price||$0.70||52-week high||$1.92|
|Prev. close||$0.67||52-week low||$0.40|
|Day high||$0.70||Avg. volume||187,485|
|50-day MA||$0.58||Dividend yield||N/A|
|200-day MA||$0.80||Market Cap||36.76M|
BTCY Stock Price Chart Interactive Chart >
BTCY Stock Summary
- With a market capitalization of $32,976,920, BIOTRICITY INC has a greater market value than only 11.42% of US stocks.
- The capital turnover (annual revenue relative to shareholder's equity) for BTCY is -0.58 -- better than just 5.98% of US stocks.
- Equity multiplier, or assets relative to shareholders' equity, comes in at -1.25 for BIOTRICITY INC; that's greater than it is for merely 5.48% of US stocks.
- Stocks that are quantitatively similar to BTCY, based on their financial statements, market capitalization, and price volatility, are BSQR, MYGN, PLPC, JFIN, and BRC.
- BTCY's SEC filings can be seen here. And to visit BIOTRICITY INC's official web site, go to www.biotricity.com.
BTCY Valuation Summary
- BTCY's price/sales ratio is 3.8; this is 72.73% higher than that of the median Healthcare stock.
- Over the past 64 months, BTCY's price/sales ratio has gone NA NA.
Below are key valuation metrics over time for BTCY.
BTCY's Quality FactorsThe “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
- BTCY has a Quality Grade of D, ranking ahead of 17.94% of graded US stocks.
- BTCY's asset turnover comes in at 1.211 -- ranking 13th of 186 Medical Equipment stocks.
- BDX, MYO, and DXCM are the stocks whose asset turnover ratios are most correlated with BTCY.
The table below shows BTCY's key quality metrics over time.
|Period||Asset Turnover||Gross Margin||ROIC|
BTCY Price Target
For more insight on analysts targets of BTCY, see our BTCY price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.
|Average Price Target||$6.50||Average Broker Recommendation||1.5 (Moderate Buy)|
Biotricity Inc. (BTCY) Company Bio
Biotricity, Inc. is a medical technology company, which is focused on biometric data monitoring solutions. It also involves in delivering, remote monitoring solutions to the medical, healthcare, and consumer markets, with a focus on diagnostic and post-diagnostic solutions for lifestyle and chronic illnesses. The firm’s FDA-approved Bioflux MCT technology, is comprised of a monitoring device and software components, which is made available to the market, in order to assess, establish and develop sales processes, and market dynamics. The company was founded by Waqaas Al-Siddiq and Peter McGoldrick on August 29, 2012 and is headquartered in Redwood City, CA.
Most Popular Stories View All
BTCY Latest News Stream
|Loading, please wait...|
BTCY Latest Social Stream
View Full BTCY Social Stream
Latest BTCY News From Around the Web
Below are the latest news stories about BIOTRICITY INC that investors may wish to consider to help them evaluate BTCY as an investment opportunity.
Biotricity Reaches $13M Revenue Run Rate in April 2023 on Accelerating Growth
Biotricity Inc. (NASDAQ:BTCY) ("Biotricity" or the "Company"), a leading medical diagnostic and consumer healthcare technology company, today reported that it reached a record $13 million annualized revenue run rate in April -- further extending its growth by over eight percent from the $12 million run rate it announced for March 2023.
Biotricity's Founder & CEO Waqaas Al-Siddiq to Present at World Heart Summit May 19-21 in Geneva, Switzerland
/ Biotricity Inc. (NASDAQ:BTCY) ("Biotricity" or the "Company"), a leading medical diagnostic and consumer healthcare technology company, today announced that its Founder & CEO Waqaas Al-Siddiq will be speaking at the World Heart Summit 2023 taking place in Geneva, Switzerland on May 19-21.
New Report Reveals Medtech Company Biotricity Decreased Patient Spending By Millions While Delivering Life-Saving Products
Biotricity Inc. (NASDAQ:BTCY), a medical technology company committed to improving healthcare by developing solutions that aid in chronic disease prevention and management, is taking action to tackle the unmet need in cardiovascular diseases (CVDs). CVDs account for around 17.9 million deaths each year, making them the leading cause of death globally.
Biotricity Reaches $12M Revenue Run Rate in March with Promising Future Growth Ahead
/ Biotricity Inc. (NASDAQ:BTCY) ("Biotricity" or the "Company"), a leading medical diagnostic and consumer healthcare technology company, today reported that it reached a record $12 million annualized revenue run rate in March 2023.
Leading Medical Biometric Firm Biotricity Releases First Corporate Impact Report
/ Biotricity, Inc. (NASDAQ:BTCY) ("Biotricity" or the "Company"), a leading medical diagnostic and consumer healthcare technology company, has released its first Corporate Impact Report- revealing that the company's remote, clinical-grade diagnostic devices are inducing "better patient outcomes and substantial cost savings" across the nation.
BTCY Price Returns
Continue Researching BTCYWant to see what other sources are saying about Biotricity Inc's financials and stock price? Try the links below:
Biotricity Inc (BTCY) Stock Price | Nasdaq
Biotricity Inc (BTCY) Stock Quote, History and News - Yahoo Finance
Biotricity Inc (BTCY) Stock Price and Basic Information | MarketWatch
Loading social stream, please wait...